Top 10 Companies in the (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole Market (2026): Market Leaders Powering Global Pharmaceutical Intermediates

MARKET INSIGHTS

Global (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole market size was valued at USD 18.4 million in 2025. The market is projected to grow from USD 19.7 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.1% during the forecast period.

(R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole is a chiral indole-based compound bearing a bromine substituent at the 5-position and a (1-methylpyrrolidin-2-yl)methyl side chain at the 3-position. It serves primarily as a key pharmaceutical intermediate and reference standard in the synthesis of pharmacologically active molecules, particularly in the development of serotonergic agents and neurological research compounds.

The market is advancing steadily, driven by increasing demand for high-purity chiral intermediates in drug discovery and the growing focus on central nervous system (CNS) therapeutics. Furthermore, the expansion of contract research and contract manufacturing organizations (CROs and CMOs) globally continues to support procurement of specialized building blocks such as this compound. Key suppliers operating in this space include Sigma-Aldrich (Merck KGaA), TCI Chemicals, and Cayman Chemical, among others offering this compound within their fine chemicals and research reagents portfolios.

(R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole Market – View in Detailed Research Report

---

🔟 1. Capot Chemical Co., Ltd.

Headquarters: Nanjing, China
Key Offering: High-purity (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole for pharmaceutical intermediates

Capot Chemical has established a robust GMP-compliant manufacturing facility that delivers the chiral indole with 99.8% enantiomeric excess, meeting stringent regulatory requirements for CNS drug development.

Sustainability & Growth Initiatives:

• Implementation of continuous flow synthesis to reduce solvent usage by 35%
• Investment in renewable energy-powered production lines
• Strategic partnerships with major CROs to expand market reach

---

9️⃣ 2. Hairui Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical-grade (R)-indole intermediates for Varenicline and related CNS agents

Hairui Chemical focuses on scalable chiral resolution processes, achieving high yield and purity while maintaining cost competitiveness for generic drug manufacturers.

Sustainability & Growth Initiatives:

• Adoption of green bromination catalysts to minimize hazardous waste
• Collaboration with universities to develop next-generation enantioselective catalysts
• Expansion into emerging markets through localized production hubs

---

8️⃣ 3. Chemenu Inc.

Headquarters: Shanghai, China
Key Offering: Custom synthesis of chiral indole intermediates for research and industrial applications

Chemenu leverages modular synthesis platforms to deliver tailored solutions for academic and biotech clients, ensuring rapid turnaround and compliance with regulatory standards.

Sustainability & Growth Initiatives:

• Integration of solvent-recycling units to lower environmental impact
• Partnerships with contract manufacturing organizations for joint R&D projects
• Focus on cost-optimization through process intensification

---

7️⃣ 4. PharmaBlock Sciences Co., Ltd.

Headquarters: Beijing, China
Key Offering: High-purity (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole for pharmaceutical intermediates

PharmaBlock Sciences provides GMP-certified production with rigorous quality control, supporting large-scale synthesis of Varenicline and other CNS therapeutics.

Sustainability & Growth Initiatives:

• Implementation of energy-efficient crystallization processes
• Adoption of biodegradable solvent systems
• Strategic alliances with global pharma companies for technology transfer

---

6️⃣ 5. Biosynth Carbosynth

Headquarters: Geneva, Switzerland
Key Offering: Reference-grade (R)-indole intermediates for academic and industrial research

Biosynth Carbosynth specializes in custom synthesis and provides detailed analytical data to support drug discovery programs.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks for indole synthesis
• Collaboration with EU-funded green chemistry projects
• Expansion of high-purity product portfolio for CNS applications

---

5️⃣ 6. Enamine Ltd.

Headquarters: Kiev, Ukraine
Key Offering: Enantiomerically pure (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole for research and development

Enamine offers a global distribution network, ensuring timely delivery of high-quality intermediates to CROs and pharmaceutical manufacturers.

Sustainability & Growth Initiatives:

• Implementation of green synthesis protocols to reduce hazardous waste
• Investment in digital supply chain transparency
• Partnerships with academic institutions for early-stage drug discovery

---

4️⃣ 7. Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: High-purity (R)-indole intermediates for pharmaceutical and specialty chemical markets

Finetech focuses on process optimization and cost-efficiency, delivering scalable production for both domestic and international clients.

Sustainability & Growth Initiatives:

• Adoption of catalytic hydrogenation to reduce solvent usage
• Integration of waste-recycling systems
• Expansion into emerging markets through local manufacturing plants

---

3️⃣ 8. Hunan Aslsen Biotechnology Co., Ltd.

Headquarters: Changsha, China
Key Offering: Custom synthesis of (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole for research and industrial applications

Hunan Aslsen Biotechnology offers flexible production capacities, enabling rapid prototyping for academic and biotech startups.

Sustainability & Growth Initiatives:

• Implementation of green chemistry protocols for bromination steps
• Collaboration with regional universities for technology development
• Focus on reducing carbon footprint through energy-efficient processes

---

2️⃣ 9. Aikon Chemical Ltd.

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical-grade (R)-indole intermediates for CNS drug development

Aikon Chemical delivers high-quality intermediates with stringent purity controls, supporting global pharmaceutical manufacturers.

Sustainability & Growth Initiatives:

• Adoption of solvent-free synthesis routes
• Investment in renewable energy for production facilities
• Strategic alliances with CROs for joint development projects

---

1️⃣ 10. Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High-purity (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole for pharmaceutical intermediates and reference standards

Shanghai Trustin Chemical combines advanced synthesis technologies with robust quality systems to meet global regulatory requirements.

Sustainability & Growth Initiatives:

• Implementation of green chemistry practices across the production chain
• Collaboration with international partners for technology exchange
• Expansion of product portfolio to include related indole derivatives

---

Download FREE Sample Report: (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole Market – View in Detailed Research Report

Get Full Report: (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole Market – View in Detailed Research Report

---

Outlook: The Future of (R)-5-Bromo-3-[(1-Methyl-2-Pyrrolidinyl)Methyl]-1H-Indole Market

The market is poised for continued growth driven by the expansion of CNS therapeutics and the increasing adoption of chiral intermediates in drug discovery. Advances in enantioselective synthesis and continuous flow technologies are expected to lower production costs and enhance yield, making high-purity intermediates more accessible to generic manufacturers.

---

Key Trends Shaping the Market

• Rapid adoption of green chemistry protocols to reduce environmental impact and comply with tightening regulations.
• Growing focus on personalized medicine and biosimilar development, increasing demand for reference standards.
• Strategic partnerships between OEMs and contract manufacturers to accelerate product development pipelines.
• Expansion of manufacturing capabilities in Asia-Pacific, strengthening supply chain resilience.
• Emerging applications in neurodegenerative disease therapeutics, broadening the market beyond smoking cessation.